Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company” ...

Study authors concluded that microdrop delivery using the Nanodropper adaptor improved intraocular pressure reduction while decreasing premature bottle exhaustion and non-systemic adverse effects, ...

Providence Medical Technology’s latest randomized controlled trial is designed to once again challenge the standard of care ...

A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. This is an ...

OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision ...

A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma ...

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality ...

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027Select TIGeR-PaC Cancer Centers ...

Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...

Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a ...